Trials / Completed
CompletedNCT01459081
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 298 (actual)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanamivir | 10 mg inhaled by mouth, twice daily, for 5 days |
| DRUG | Placebo | inhaled by mouth, twice daily, for 5 days |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-10-25
- Last updated
- 2013-01-16
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01459081. Inclusion in this directory is not an endorsement.